FDA Grants Priority Review To Genentech’s Cancer Immunotherapy TECENTRIQ – Nasdaq
Nasdaq |
FDA Grants Priority Review To Genentech's Cancer Immunotherapy TECENTRIQ
Nasdaq (RTTNews.com) – Genentech, a member of the Roche Group ( RHHBY ), said that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application or sBLA and granted Priority Review for TECENTRIQ or atezolizumab … FDA Grants Priority Review to Genentech's Cancer Immunotherapy TECENTRIQ (Atezolizumab) for Initial Treatment of … Roche's Tecentriq combination to get speedy FDA review |
